Global Dupuytren’s Disease Market, By Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others), Diagnosis (Physical Examination, X-Ray, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.
Dupuytren’s Disease Market Analysis and Size:
The increasing prevalence acts as one of the major factors driving the growth of global dupuytren’s disease market. The advancements in medical technology and increasing health care infrastructure expenditure accelerate the global dupuytren’s disease market growth. The disease's rising prevalence is driving considerable growth in the market. According to a recent study published in the Journal of Hand Surgery, there has been a significant increase in diagnosed cases, indicating a larger patient population in need of treatment alternatives. As a result, pharmaceutical firms and medical device makers have boosted their spending in research and development to fulfil the demand for better management techniques. Furthermore, a 2021 population study in the United States discovered that up to 7% of the population had clinical symptoms, with more than one-third of that group afflicted by the impact of dupuytren's contractures on everyday function.
Data Bridge Market Research analyses that the global dupuytren’s disease Market which was USD 39.8 billion in 2022, is expected to reach USD 145.7 billion by 2030, and is expected to undergo a CAGR of 22.20% during the forecast period of 2023 to 2030. “Surgery, Radiation Therapy” segment dominates the treatment segment of the global dupuytren’s disease market owing to the advancements in technology have led to the development of advancements in drug products for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dupuytren’s Disease Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others), Diagnosis (Physical Examination, X-Ray, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Merck & Co., Inc. (U.S.), Fresenius Kabi AG (Germany.), Bristol-Myers Squibb Company (U.S.), Endo International plc (Ireland.), Pfizer Inc. (U.S.), Hikma Pharmaceuticals PLC (U.S.), Spear Pharmaceuticals. (U.S.), Actiza Pharmaceutical Private Limited (India.), Nantong Jinghua Pharmaceutical Co., Ltd. (U.S.), GSK plc (U.S.), Abbott (U.S.), Bayer AG(U.S.), AstraZeneca (U.S.), Johnson & Johnson Services Ltd. (U.S.), Cipla Inc. (U.S.), LEO Pharma A/S (U.S.), Sumitomo Dainippon Pharma Co., Ltd. (Japan.), Novartis AG(U.S.), Sanofi (France), Aurobindo Pharma (India), and Lupin (India)
|
|
Market Opportunities
|
|
Market Definition
Dupuytren's disease, also known as dupuytren's contracture, is a progressive condition that affects the hand and fingers. It is characterized by the thickening and tightening of the connective tissue called the palmar fascia, which lies beneath the skin of the palm and fingers. This fibrous tissue forms nodules and cords that can gradually contract, leading to the curling and bending of the affected fingers towards the palm.
Global Dupuytren’s Disease Market dynamics
Drivers
- Increasing Prevalence
The prevalence of dupuytren's disease is rising globally, particularly in aging populations. Factors such as genetics, gender, and certain lifestyle choices contribute to its development. The growing number of affected individuals creates a significant market demand for effective treatments
- Advancements in Diagnostic Techniques:
Improvements in diagnostic techniques, including imaging technologies and biomarker identification, have facilitated early and accurate detection of dupuytren's disease. Early diagnosis allows for timely intervention and treatment, driving the demand for effective therapies.
- Technological Advancements in Treatment Options
The field of dupuytren's disease treatment has witnessed technological advancements, leading to the development of novel and minimally invasive treatment options. Procedures such as needle aponeurotomy, collagenase injection, and radiotherapy have gained popularity, offering alternatives to traditional surgical approaches. These advancements provide patients with more treatment choices, driving market growth.
Opportunities
- Growing Patient Awareness
Increasing awareness about dupuytren's disease among patients, healthcare professionals, and the general population has contributed to the diagnosis and treatment-seeking behaviour Educational initiatives, patient support groups, and online resources have played a crucial role in enhancing awareness and driving market growth
- Rising Demand for Non-Surgical Interventions
Many patients prefer non-surgical interventions that are less invasive, have shorter recovery times, and offer comparable outcomes to traditional surgical procedures. The development of non-surgical treatments such as injectable collagenase has gained traction and is expected to drive market growth.
Restraints/Challenges
- Lack of Awareness
One of the significant challenges is the limited awareness and understanding of Dupuytren's disease among the general population and even some healthcare professionals. This can lead to delays in diagnosis and treatment, as well as underreporting of the condition.
- Misdiagnosis and Underdiagnosis
Dupuytren's disease can often be misdiagnosed or overlooked, especially in its early stages. Its symptoms, such as nodules or thickened cords in the palm, can be mistaken for other conditions or considered insignificant. This can result in delayed intervention and progression of the disease.
This global dupuytren’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dupuytren’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO, AJOVY, UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business
- In November 2022, A wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Sun Pharma Advanced Research Company Ltd.
Global Dupuytren’s Disease Market scope
The global dupuytren’s disease market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Surgery
- Radiation Therapy
- Needle Aponeurotomy
- Steroid Shot
- Enzyme Injection
- Occupational Therapy
- Others
Diagnosis
- Physical Examination
- X-Ray
- Others
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Parenteral
- Others
End Users
- Clinic
- Hospital
- Others
Global Dupuytren’s Disease Market Regional Analysis/Insights
The global dupuytren’s disease market is analysed and market size insights and trends are the basis treatment, diagnosis, dosage, route of administration, end users as referenced above.
The countries covered in the global dupuytren’s disease market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
North America dominates the global dupuytren’s disease market due to the presence of major key players, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region.
Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Dupuytren’s Disease Market Share Analysis
The global dupuytren’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global dupuytren’s disease market.
Some of the major players operating in the ssglobal dupuytren’s disease market are:
- Merck & Co., Inc.(U.S.)
- Fresenius Kabi AG (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Endo International plc (Ireland)
- Pfizer Inc. (U.S.)
- Hikma Pharmaceuticals PLC (U.S.)
- Spear Pharmaceuticals. (U.S.)
- Actiza Pharmaceutical Private Limited (India)
- Nantong Jinghua Pharmaceutical Co., Ltd. (U.S.)
- GSK plc (U.S.)
- Abbott (U.S.)
- Bayer AG (U.S.)
- AstraZeneca (U.S.)
- Johnson & Johnson Services Ltd. (U.S.)
- Cipla Inc. (U.S.)
- LEO Pharma A/S (U.S.)
- Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Novartis AG (U.S.)
- Sanofi (France)
- Aurobindo Pharma (India)
- Lupin (India)
SKU-